Abstract 657P
Background
T cell engagers (TCE) have been a breakthrough in pts care for multiple malignancies, and the number of phase I clinical trials testing TCE is exponential. The TCE score, based on lactate dehydrogenase (LDH) (LDH > 250 U/l : +1) and C reactive protein (CRP) (CRP > 10g/l : +1) levels, that was developed on a setting cohort (presented at ASCO annual meeting in 2023, Noé Herbel et al., JCO 41, 2573-2573(2023)), was shown to be prognostic for both overall survival (OS) and progression free survival (PFS), as pts with a high score (1-2) had a shorter OS and PFS, with a median PFS of less than two months : thus not presenting a sufficient clinical benefit from the treatment. To confirm the results obtained on the setting cohort, we aimed to prospectively confirm the prognostic ability of the TCE score on a validation cohort.
Methods
Every pts treated with a CD3 TCE in a phase I CT at the drug development department (DITEP) at Gustave Roussy which were not part of the setting cohort, with at least a two months follow up, were included in the validation cohort. Biological and clinical data were prospectively collected to calculate the TCE score, the OS and the PFS. Biological data were collected during the screening period. Estimation of OS and PFS was made using Kaplan-Meir method and comparison using log-rank test. Cox regression model was used in univariate analysis. Predictive power of the TCE score was analyzed using Harrell's C index.
Results
A total of 70 pts treated with CD3 TCE were included in the validation cohort. Median age was 60 years old. The most represented tumor type was ovarian adenocarcinoma (21%). Kaplan-Meier, log-rank test and cox regression model showed that pts with a low score had a longer PFS (HR : 0.42, 95%CI = 0.23 - 0.78, p = 0.005), with a median PFS of 1.8 months (m) for high-risk pts and 5.5 m for low-risk pts. It was also showed that low risk pts have a longer OS (HR : 0.41, 95%CI = 0.18 - 0.93, p = 0.03, with a median 8.7 m for high-risk pts and 12.4 m for low-risk pts. TCE score’s Harrell’s C index for PFS was 0.61 and 0.62 for OS.
Conclusions
The TCE score was developed on a setting cohort to be prognostic for OS and PFS in pts treated with bispecific TCE in phase I CT. We prospectively validated this score on an independent validation cohort.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
630P - Debio 0123 + carboplatin (CP) for patients (pts) with advanced solid tumors: Safety, preliminary efficacy and determination of recommended phase II dose (RP2D)
Presenter: Hans Gelderblom
Session: Poster session 01
631P - Phase Ib expansion study of CX-5461 in patients with solid tumours and BRCA2 and/or PALB2 mutation
Presenter: Pamela Soberanis Pina
Session: Poster session 01
632P - Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors
Presenter: Chia-Chi Lin
Session: Poster session 01
633P - First-in-human dose-escalation study of basroparib (STP1002) in patients with advanced-stage solid tumors
Presenter: Christopher Lieu
Session: Poster session 01
634P - First results from phase I/II study of CTS2190, a novel small-molecule inhibitor of type I PRMTs, in patients with advanced solid tumors
Presenter: Xiangdong Cheng
Session: Poster session 01
635P - The phase I dose-escalation study of TSN084, a multi-kinase inhibitor, in patients with advanced malignant tumors
Presenter: Jie Wang
Session: Poster session 01
636P - Tucatinib and trastuzumab in advanced cancers with HER2 mutations or amplification: A molecular screening and therapeutics (MoST) program substudy
Presenter: Benjamin Kong
Session: Poster session 01
637P - AC699, a novel chimeric estrogen receptor degrader, in a phase I study in breast cancer
Presenter: Erika Hamilton
Session: Poster session 01
638P - Final results of IMPACT 2, a randomized study evaluating molecular profiling and targeted agents in metastatic cancer at MD Anderson Cancer Center
Presenter: Apostolia Maria Tsimberidou
Session: Poster session 01
639P - Serial ctDNA profiling as a catalyst for tailored therapeutics in advanced cancer: Analysis of two precision medicine studies
Presenter: Sophie Cousin
Session: Poster session 01